EYPT vs. CAMT, TXG, ALNT, AEHR, TRNS, CTKB, LAB, SENS, FEIM, and QSI
Should you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include Camtek (CAMT), 10x Genomics (TXG), Allient (ALNT), Aehr Test Systems (AEHR), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry.
Eyepoint Pharmaceuticals vs. Its Competitors
Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Camtek (NASDAQ:CAMT) are both measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.
In the previous week, Camtek had 4 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 11 mentions for Camtek and 7 mentions for Eyepoint Pharmaceuticals. Camtek's average media sentiment score of 1.36 beat Eyepoint Pharmaceuticals' score of 1.29 indicating that Camtek is being referred to more favorably in the news media.
Eyepoint Pharmaceuticals has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Camtek has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Camtek has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.
Camtek has a net margin of 28.36% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. Camtek's return on equity of 23.95% beat Eyepoint Pharmaceuticals' return on equity.
99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.9% of Camtek shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 79.4% of Camtek shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Eyepoint Pharmaceuticals presently has a consensus price target of $26.86, suggesting a potential upside of 101.48%. Camtek has a consensus price target of $96.10, suggesting a potential upside of 14.26%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Camtek.
Summary
Camtek beats Eyepoint Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Eyepoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyepoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 9/12/2025 by MarketBeat.com Staff
Free EYPT Stock Alerts